Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Adult
Aged
Anaplastic Lymphoma Kinase
/ genetics
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Computational Biology
/ methods
Crizotinib
/ pharmacology
DNA Mutational Analysis
Drug Resistance, Neoplasm
/ genetics
Female
Gene Rearrangement
Humans
Immunohistochemistry
Immunophenotyping
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Neoplastic Cells, Circulating
/ metabolism
Protein Kinase Inhibitors
/ pharmacology
Whole Genome Sequencing
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
09
04
2019
revised:
04
07
2019
accepted:
13
08
2019
pubmed:
24
8
2019
medline:
12
9
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
Patients with anaplastic lymphoma kinase ( Resistance mutations were investigated in CTCs isolated at the single-cell level from patients at disease progression on crizotinib ( Multiple mutations in various genes in ALK-independent pathways were predominantly identified in CTCs of crizotinib-resistant patients. The RTK-KRAS ( Our results highlight the genetic heterogeneity and clinical utility of CTCs to identify therapeutic resistance mutations in
Identifiants
pubmed: 31439588
pii: 1078-0432.CCR-19-1176
doi: 10.1158/1078-0432.CCR-19-1176
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Protein Kinase Inhibitors
0
Crizotinib
53AH36668S
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6671-6682Informations de copyright
©2019 American Association for Cancer Research.